6-Mercaptopurine oral suspension for the treatment of acute lymphoblastic leukaemia

摘要

A liquid pharmaceutical composition for use in the treatment of acute lymphoblastic leukaemia (ALL), comprising 6-mercaptopurine (6-MP) or a salt, hydrate or solvate thereof, wherein the composition is a suspension for oral administration. Preferably the composition is an aqueous oral dosage comprising 10-30 mg/mL (1.0-3.0% w/v) of 6-mercaptopurine monohydrate as suspended particles of diameter in the range of 3-85mm. The composition may be useful in particular as an oral paediatric formulation for the treatment of ALL in children. A kit comprising the composition and a plurality of syringes of different volume for accurate dosing and administration is also claimed.